市場調査レポート

商品コード

1365752

便秘治療市場：製品タイプ別、疾患タイプ別、処方タイプ別、流通チャネル別：世界の機会分析と産業予測、2023～2032年

Constipation Treatment Market By Product Type, By Disease Type, By Prescription Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日: 2023年08月01日 | 発行: Allied Market Research

| ページ情報: 英文 479 Pages | 納期: 2～3営業日

価格

PDF (Single User License)

USD 5,730 898,234円

レポートPDFを1つのPCでご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回だけ可能です。印刷したレポートの利用もPDFのライセンス保持者になります。回覧のための複製も原則NGです。

PDF (5-user License)

USD 6,450 1,011,102円

レポートPDFを5名でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回可能です。印刷したレポートの利用もPDFのライセンス保持者5名となります。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,504,896円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

便秘治療市場は2022年に59億米ドルと評価され、2023年から2032年にかけてCAGR 5.6%で成長し、2032年には101億米ドルに達すると推定されます。

便秘治療市場の成長は、便秘治療製品を製造する市場参入企業の存在感の高さ、便秘の有病率の上昇、疼痛管理のためのオピオイド使用の増加によってもたらされます。オピオイドの副作用としてよく知られているのは、消化器系への影響であり、しばしば便秘を引き起こします。この作用は、オピオイドが消化管や神経系の受容体と相互作用することによって起こる。したがって、慢性疼痛に苦しむ人口の増加が鎮痛剤の使用を促進すると予想されます。そのため、この要因によって便秘の有病率が増加し、市場の成長が促進されると予想されます。例えば、米国慢性疼痛財団によると、2022年には5,000万人の米国人が慢性疼痛、つまり3カ月以上毎日またはほとんど毎日続く痛みを抱えて生活しています。半数以上（52％）が、平均的な痛みのレベルは1～10のうち7以上であると回答しています。

さらに、座りがちなライフスタイル、食生活の乱れ、ストレスなどと関連することが多い便秘の罹患率の上昇が、便秘治療市場の成長促進要因となっています。食物繊維含有量の少ない加工食品へのシフトを含む食習慣の変化は、便秘の一因となる可能性があります。このため、その症状を緩和する治療薬に対する需要が高まっています。さらに、ストレスや精神衛生上の問題は、便通を含む消化プロセスに影響を与える可能性があります。このように、不健康なライフスタイル要因は便秘の有病率を高め、市場の成長を促進すると予想されます。

市場の定義と範囲
主な調査結果
- 影響要因
- 主な投資機会
ポーターのファイブフォース分析
市場力学
- 促進要因
  - 慢性疼痛の有病率の上昇
  - 便秘の有病率の増加
  - 便秘治療に有効な薬剤の増加
- 抑制要因
  - 薬物に伴う副作用。
  - 特発性便秘に利用可能な代替選択肢。
- 機会
  - 主要戦略の採用数の増加市場別

第4章便秘治療市場：製品タイプ別

概要
ミューオピオイド受容体拮抗薬
緩下剤
クロライドチャネル-2活性化薬
グアニル酸シクラーゼ-C（GC-C）作動薬
その他

第5章便秘治療市場：疾患タイプ別

概要
オピオイド誘発性便秘
慢性特発性便秘
便秘を伴う過敏性腸症候群

第6章便秘治療市場：処方タイプ別

概要
処方薬
市販薬

第7章便秘治療市場：流通チャネル別

概要
オンライン薬局
ドラッグストアおよび小売薬局
その他

第8章便秘治療市場：地域別

概要
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- その他
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- 韓国
- その他
ラテンアメリカ・中東・アフリカ
- ブラジル
- 南アフリカ
- サウジアラビア
- その他

第9章競争情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合ヒートマップ
主要企業のポジショニング、2022年

第10章企業プロファイル

Takeda Pharmaceutical Company Ltd.
AbbVie Inc.
Abbott Laboratories
Sanofi S.A.
Bausch Health Companies Inc.
Bayer AG
AstraZeneca plc
Ironwood Pharmaceuticals, Inc.
Prestige Consumer Healthcare Inc.
Ardelyx Inc.

図表

LIST OF TABLES

TABLE 01. GLOBAL CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 02. CONSTIPATION TREATMENT MARKET FOR MU-OPIOID RECEPTOR ANTAGONISTS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. CONSTIPATION TREATMENT MARKET FOR LAXATIVE, BY REGION, 2022-2032 ($MILLION)
TABLE 04. CONSTIPATION TREATMENT MARKET FOR CHLORIDE CHANNEL-2 ACTIVATOR, BY REGION, 2022-2032 ($MILLION)
TABLE 05. CONSTIPATION TREATMENT MARKET FOR GUANYLATE CYCLASE-C (GC-C) AGONIST, BY REGION, 2022-2032 ($MILLION)
TABLE 06. CONSTIPATION TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 07. GLOBAL CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 08. CONSTIPATION TREATMENT MARKET FOR OPIOID-INDUCED CONSTIPATION, BY REGION, 2022-2032 ($MILLION)
TABLE 09. CONSTIPATION TREATMENT MARKET FOR CHRONIC IDIOPATHIC CONSTIPATION, BY REGION, 2022-2032 ($MILLION)
TABLE 10. CONSTIPATION TREATMENT MARKET FOR IRRITABLE BOWEL SYNDROME WITH CONSTIPATION, BY REGION, 2022-2032 ($MILLION)
TABLE 11. GLOBAL CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 12. CONSTIPATION TREATMENT MARKET FOR PRESCRIBED DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 13. CONSTIPATION TREATMENT MARKET FOR OVER-THE-COUNTER DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 14. GLOBAL CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 15. CONSTIPATION TREATMENT MARKET FOR ONLINE PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 16. CONSTIPATION TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 17. CONSTIPATION TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 18. CONSTIPATION TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 20. NORTH AMERICA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 21. NORTH AMERICA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 22. NORTH AMERICA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 23. NORTH AMERICA CONSTIPATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 24. U.S. CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 25. U.S. CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 26. U.S. CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 27. U.S. CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 28. CANADA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 29. CANADA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 30. CANADA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 31. CANADA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 32. MEXICO CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 33. MEXICO CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 34. MEXICO CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 35. MEXICO CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 36. EUROPE CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 37. EUROPE CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 38. EUROPE CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 39. EUROPE CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 40. EUROPE CONSTIPATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 41. GERMANY CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 42. GERMANY CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 43. GERMANY CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 44. GERMANY CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 45. FRANCE CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 46. FRANCE CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 47. FRANCE CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 48. FRANCE CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 49. UK CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 50. UK CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 51. UK CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 52. UK CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 53. ITALY CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 54. ITALY CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 55. ITALY CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 56. ITALY CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 57. SPAIN CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 58. SPAIN CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 59. SPAIN CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 60. SPAIN CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 61. REST OF EUROPE CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 62. REST OF EUROPE CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 63. REST OF EUROPE CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 64. REST OF EUROPE CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 65. ASIA-PACIFIC CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 66. ASIA-PACIFIC CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 67. ASIA-PACIFIC CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 68. ASIA-PACIFIC CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 69. ASIA-PACIFIC CONSTIPATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 70. JAPAN CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 71. JAPAN CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 72. JAPAN CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 73. JAPAN CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 74. CHINA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 75. CHINA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 76. CHINA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 77. CHINA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 78. INDIA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 79. INDIA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 80. INDIA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 81. INDIA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 82. AUSTRALIA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 83. AUSTRALIA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 84. AUSTRALIA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 85. AUSTRALIA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 86. SOUTH KOREA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 87. SOUTH KOREA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 88. SOUTH KOREA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 89. SOUTH KOREA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 90. REST OF EUROPE CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 91. REST OF EUROPE CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 92. REST OF EUROPE CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 93. REST OF EUROPE CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 94. LAMEA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 95. LAMEA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 96. LAMEA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 97. LAMEA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 98. LAMEA CONSTIPATION TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 99. BRAZIL CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 100. BRAZIL CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 101. BRAZIL CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 102. BRAZIL CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 103. SOUTH AFRICA, CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 104. SOUTH AFRICA, CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 105. SOUTH AFRICA, CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 106. SOUTH AFRICA, CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 107. SAUDI ARABIA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 108. SAUDI ARABIA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 109. SAUDI ARABIA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 110. SAUDI ARABIA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 111. REST OF LAMEA CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 112. REST OF LAMEA CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 113. REST OF LAMEA CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022-2032 ($MILLION)
TABLE 114. REST OF LAMEA CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 115. TAKEDA PHARMACEUTICAL COMPANY LTD.: KEY EXECUTIVES
TABLE 116. TAKEDA PHARMACEUTICAL COMPANY LTD.: COMPANY SNAPSHOT
TABLE 117. TAKEDA PHARMACEUTICAL COMPANY LTD.: PRODUCT SEGMENTS
TABLE 118. TAKEDA PHARMACEUTICAL COMPANY LTD.: PRODUCT PORTFOLIO
TABLE 119. ABBVIE INC.: KEY EXECUTIVES
TABLE 120. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 121. ABBVIE INC.: PRODUCT SEGMENTS
TABLE 122. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 123. ABBVIE INC.: KEY STRATERGIES
TABLE 124. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 125. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 126. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 127. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 128. SANOFI S.A.: KEY EXECUTIVES
TABLE 129. SANOFI S.A.: COMPANY SNAPSHOT
TABLE 130. SANOFI S.A.: PRODUCT SEGMENTS
TABLE 131. SANOFI S.A.: PRODUCT PORTFOLIO
TABLE 132. BAUSCH HEALTH COMPANIES INC.: KEY EXECUTIVES
TABLE 133. BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
TABLE 134. BAUSCH HEALTH COMPANIES INC.: PRODUCT SEGMENTS
TABLE 135. BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
TABLE 136. BAUSCH HEALTH COMPANIES INC.: KEY STRATERGIES
TABLE 137. BAYER AG: KEY EXECUTIVES
TABLE 138. BAYER AG: COMPANY SNAPSHOT
TABLE 139. BAYER AG: PRODUCT SEGMENTS
TABLE 140. BAYER AG: PRODUCT PORTFOLIO
TABLE 141. ASTRAZENECA PLC: KEY EXECUTIVES
TABLE 142. ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 143. ASTRAZENECA PLC: PRODUCT SEGMENTS
TABLE 144. ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 145. IRONWOOD PHARMACEUTICALS, INC.: KEY EXECUTIVES
TABLE 146. IRONWOOD PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 147. IRONWOOD PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
TABLE 148. IRONWOOD PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
TABLE 149. IRONWOOD PHARMACEUTICALS, INC.: KEY STRATERGIES
TABLE 150. PRESTIGE CONSUMER HEALTHCARE INC.: KEY EXECUTIVES
TABLE 151. PRESTIGE CONSUMER HEALTHCARE INC.: COMPANY SNAPSHOT
TABLE 152. PRESTIGE CONSUMER HEALTHCARE INC.: PRODUCT SEGMENTS
TABLE 153. PRESTIGE CONSUMER HEALTHCARE INC.: PRODUCT PORTFOLIO
TABLE 154. ARDELYX INC.: KEY EXECUTIVES
TABLE 155. ARDELYX INC.: COMPANY SNAPSHOT
TABLE 156. ARDELYX INC.: PRODUCT SEGMENTS
TABLE 157. ARDELYX INC.: PRODUCT PORTFOLIO
TABLE 158. ARDELYX INC.: KEY STRATERGIES

LIST OF FIGURES

FIGURE 01. CONSTIPATION TREATMENT MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF CONSTIPATION TREATMENT MARKET,2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN CONSTIPATION TREATMENT MARKET (2023-2032)
FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW THREAT OF NEW ENTRANTS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. LOW INTENSITY OF RIVALRY
FIGURE 08. LOW BARGAINING POWER OF BUYERS
FIGURE 09. GLOBAL CONSTIPATION TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 10. CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE, 2022 AND 2032(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF CONSTIPATION TREATMENT MARKET FOR MU-OPIOID RECEPTOR ANTAGONISTS, BY COUNTRY 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CONSTIPATION TREATMENT MARKET FOR LAXATIVE, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CONSTIPATION TREATMENT MARKET FOR CHLORIDE CHANNEL-2 ACTIVATOR, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CONSTIPATION TREATMENT MARKET FOR GUANYLATE CYCLASE-C (GC-C) AGONIST, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CONSTIPATION TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE, 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CONSTIPATION TREATMENT MARKET FOR OPIOID-INDUCED CONSTIPATION, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CONSTIPATION TREATMENT MARKET FOR CHRONIC IDIOPATHIC CONSTIPATION, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF CONSTIPATION TREATMENT MARKET FOR IRRITABLE BOWEL SYNDROME WITH CONSTIPATION, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE, 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF CONSTIPATION TREATMENT MARKET FOR PRESCRIBED DRUGS, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF CONSTIPATION TREATMENT MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY 2022 AND 2032(%)
FIGURE 23. CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF CONSTIPATION TREATMENT MARKET FOR ONLINE PHARMACY, BY COUNTRY 2022 AND 2032(%)
FIGURE 25. COMPARATIVE SHARE ANALYSIS OF CONSTIPATION TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACY, BY COUNTRY 2022 AND 2032(%)
FIGURE 26. COMPARATIVE SHARE ANALYSIS OF CONSTIPATION TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 27. CONSTIPATION TREATMENT MARKET BY REGION, 2022 AND 2032(%)
FIGURE 28. U.S. CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 29. CANADA CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 30. MEXICO CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 31. GERMANY CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 32. FRANCE CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 33. UK CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 34. ITALY CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 35. SPAIN CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 36. REST OF EUROPE CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 37. JAPAN CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 38. CHINA CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 39. INDIA CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 40. AUSTRALIA CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 41. SOUTH KOREA CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 42. REST OF EUROPE CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 43. BRAZIL CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 44. SOUTH AFRICA, CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 45. SAUDI ARABIA CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 46. REST OF LAMEA CONSTIPATION TREATMENT MARKET, 2022-2032 ($MILLION)
FIGURE 47. TOP WINNING STRATEGIES, BY YEAR (2022-2023)
FIGURE 48. TOP WINNING STRATEGIES, BY DEVELOPMENT (2022-2023)
FIGURE 49. TOP WINNING STRATEGIES, BY COMPANY (2022-2023)
FIGURE 50. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 51. COMPETITIVE DASHBOARD
FIGURE 52. COMPETITIVE HEATMAP: CONSTIPATION TREATMENT MARKET
FIGURE 53. TOP PLAYER POSITIONING, 2022
FIGURE 54. TAKEDA PHARMACEUTICAL COMPANY LTD.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 55. TAKEDA PHARMACEUTICAL COMPANY LTD.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 56. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 57. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 58. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 59. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
FIGURE 60. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 61. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 62. SANOFI S.A.: NET SALES, 2020-2022 ($MILLION)
FIGURE 63. SANOFI S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 64. SANOFI S.A.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 65. BAUSCH HEALTH COMPANIES INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 66. BAUSCH HEALTH COMPANIES INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 67. BAUSCH HEALTH COMPANIES INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 68. BAYER AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 69. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 70. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 71. ASTRAZENECA PLC: NET SALES, 2020-2022 ($MILLION)
FIGURE 72. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 73. IRONWOOD PHARMACEUTICALS, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 74. IRONWOOD PHARMACEUTICALS, INC.: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
FIGURE 75. PRESTIGE CONSUMER HEALTHCARE INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 76. PRESTIGE CONSUMER HEALTHCARE INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 77. PRESTIGE CONSUMER HEALTHCARE INC.: REVENUE SHARE BY REGION, 2021 (%)

Product Code: A08195

According to a new report published by Allied Market Research, titled, "Constipation Treatment Market," The constipation treatment market was valued at $5.9 billion in 2022, and is estimated to reach $10.1 billion by 2032, growing at a CAGR of 5.6% from 2023 to 2032.

The constipation treatment market growth is driven by high presence of market players who manufacture constipation treatment products, rise in prevalence of constipation, and increase in use of opioids for pain management. The well-known side effects of opioids are their impact on the gastrointestinal system, often causing constipation. This effect occurs due to the way opioids interact with receptors in the gastrointestinal tract and the nervous system. Thus, rise in population suffering from chronic pain is anticipated to drive the use of pain killers. Therefore, this factor is anticipated to increase in prevalence of constipation and boost the growth of market. For instance, according to U.S. Chronic Pain Foundation, in 2022, 50 million Americans live with chronic pain, or pain that lasts most days or every day for three months or more. More than half (52%) said their average pain level is 7 or more on a scale of 1-10.

Moreover, rising incidence of constipation, often linked to sedentary lifestyles, poor dietary habits, and stress, is a primary driver for the growth of the constipation treatment market. Changes in dietary habits, including a shift toward processed foods with lower fiber content, can contribute to constipation. This drives the demand for treatments to alleviate its symptoms. In addition, stress and mental health issues can impact digestive processes, including bowel movements. Thus, unhealthy lifestyle factors are anticipated to increase in prevalence of constipation and drive the growth of market.

In addition, rise in number of geriatric populations is anticipated to drive the growth of the constipation treatment market. As people age, the digestive system tends to slow down, including the movement of food and waste through the intestines. This slower transit time can lead to the accumulation of stool in the colon and contribute to constipation. Thus, rise in number of geriatric populations is anticipated to increase in prevalence of constipation. For instance, according to World Health Organization (WHO), it was estimated that, by 2030, 1 in 6 people in the world will be aged 60 years or over. At this time, the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world's population of people aged 60 years and older will double (2.1 billion). The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million. Moreover, according to Frontiers in Public Health, in 2022, it was reported that, the prevalence of constipation was 17.60% in elderly people aged 65 years and old.

The constipation treatment market is segmented based on product type, disease type, prescription type, distribution channel, and region. By product type, the market is classified into Mu-opioid receptor antagonists, laxative, chloride channel-2 activator, guanylate cyclase-C (GC-C) agonist, and others. Others includes selective 5-ht agonists and sodium-proton-exchanger subtype 3 (NHE3) inhibitor. As per disease type, the constipation treatment market is segmented into opioid-induced constipation, chronic idiopathic constipation, and irritable bowel syndrome with constipation. According to prescription type, the market is classified into prescribed drugs and over-the-counter drugs. By distribution channel, the market is divided into online pharmacy, drug store & retail pharmacy and others. Others includes hospital pharmacies and general stores.

Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Major key players that operate in the global constipation treatment market are Salix Pharma (Bausch Health), Takeda Pharmaceutical, AbbVie, Abbott, Sanofi, Bayer AG, AstraZeneca plc., Ironwood Pharmaceuticals, Inc., Prestige Consumer Healthcare Inc. and Ardelyx. Key players operating in the market have adopted product approval, product launch, acquisition, and agreement as their key strategies to expand their constipation treatment market share.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the constipation treatment market analysis from 2022 to 2032 to identify the prevailing constipation treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the constipation treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global constipation treatment market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

Product Benchmarking / Product specification and applications
Upcoming/New Entrant by Regions
New Product Development/ Product Matrix of Key Players
Patient/epidemiology data at country, region, global level
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
SWOT Analysis

Key Market Segments

By Product Type

Others
Mu-Opioid Receptor Antagonists
Laxative
Chloride Channel-2 Activator
Guanylate Cyclase-C (GC-C) Agonist

By Disease Type

Opioid-Induced Constipation
Chronic Idiopathic Constipation
Irritable Bowel Syndrome with Constipation

By Prescription Type

Prescribed Drugs
Over-the-Counter Drugs

By Distribution Channel

Online Pharmacy
Drug Store and Retail Pharmacy
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Europe
LAMEA
- Brazil
- South Africa,
- Saudi Arabia
- Rest of LAMEA

Key Market Players:

Abbott Laboratories
Bausch Health Companies Inc.
Bayer AG
Ironwood Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Ltd.
Prestige Consumer Healthcare Inc.
Ardelyx Inc.
Sanofi S.A.
AstraZeneca plc
AbbVie Inc.

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rise in prevalence of chronic pain
  - 3.4.1.2. Increase in prevalence of constipation.
  - 3.4.1.3. Rise in availability of effective drugs for constipation treatment

3.4.2. Restraints
- 3.4.2.1. Side effects associated with drugs.
- 3.4.2.2. Substitutional options available for idiopathic constipation.

3.4.3. Opportunities
- 3.4.3.1. Rise in number of adoptions of key strategies by market.

CHAPTER 4: CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Mu-Opioid Receptor Antagonists
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Laxative
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Chloride Channel-2 Activator
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
4.5. Guanylate Cyclase-C (GC-C) Agonist
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
4.6. Others
- 4.6.1. Key market trends, growth factors and opportunities
- 4.6.2. Market size and forecast, by region
- 4.6.3. Market share analysis by country

CHAPTER 5: CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Opioid-Induced Constipation
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Chronic Idiopathic Constipation
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Irritable Bowel Syndrome with Constipation
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Prescribed Drugs
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Over-the-Counter Drugs
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country

CHAPTER 7: CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL

7.1. Overview
- 7.1.1. Market size and forecast
7.2. Online Pharmacy
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by region
- 7.2.3. Market share analysis by country
7.3. Drug Store and Retail Pharmacy
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by region
- 7.3.3. Market share analysis by country
7.4. Others
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by region
- 7.4.3. Market share analysis by country

CHAPTER 8: CONSTIPATION TREATMENT MARKET, BY REGION

8.1. Overview
- 8.1.1. Market size and forecast By Region
8.2. North America
- 8.2.1. Key market trends, growth factors and opportunities
- 8.2.2. Market size and forecast, by Product Type
- 8.2.3. Market size and forecast, by Disease Type
- 8.2.4. Market size and forecast, by Prescription Type
- 8.2.5. Market size and forecast, by Distribution Channel
- 8.2.6. Market size and forecast, by country
  - 8.2.6.1. U.S.
  - 8.2.6.1.1. Market size and forecast, by Product Type
  - 8.2.6.1.2. Market size and forecast, by Disease Type
  - 8.2.6.1.3. Market size and forecast, by Prescription Type
  - 8.2.6.1.4. Market size and forecast, by Distribution Channel
  - 8.2.6.2. Canada
  - 8.2.6.2.1. Market size and forecast, by Product Type
  - 8.2.6.2.2. Market size and forecast, by Disease Type
  - 8.2.6.2.3. Market size and forecast, by Prescription Type
  - 8.2.6.2.4. Market size and forecast, by Distribution Channel
  - 8.2.6.3. Mexico
  - 8.2.6.3.1. Market size and forecast, by Product Type
  - 8.2.6.3.2. Market size and forecast, by Disease Type
  - 8.2.6.3.3. Market size and forecast, by Prescription Type
  - 8.2.6.3.4. Market size and forecast, by Distribution Channel
8.3. Europe
- 8.3.1. Key market trends, growth factors and opportunities
- 8.3.2. Market size and forecast, by Product Type
- 8.3.3. Market size and forecast, by Disease Type
- 8.3.4. Market size and forecast, by Prescription Type
- 8.3.5. Market size and forecast, by Distribution Channel
- 8.3.6. Market size and forecast, by country
  - 8.3.6.1. Germany
  - 8.3.6.1.1. Market size and forecast, by Product Type
  - 8.3.6.1.2. Market size and forecast, by Disease Type
  - 8.3.6.1.3. Market size and forecast, by Prescription Type
  - 8.3.6.1.4. Market size and forecast, by Distribution Channel
  - 8.3.6.2. France
  - 8.3.6.2.1. Market size and forecast, by Product Type
  - 8.3.6.2.2. Market size and forecast, by Disease Type
  - 8.3.6.2.3. Market size and forecast, by Prescription Type
  - 8.3.6.2.4. Market size and forecast, by Distribution Channel
  - 8.3.6.3. UK
  - 8.3.6.3.1. Market size and forecast, by Product Type
  - 8.3.6.3.2. Market size and forecast, by Disease Type
  - 8.3.6.3.3. Market size and forecast, by Prescription Type
  - 8.3.6.3.4. Market size and forecast, by Distribution Channel
  - 8.3.6.4. Italy
  - 8.3.6.4.1. Market size and forecast, by Product Type
  - 8.3.6.4.2. Market size and forecast, by Disease Type
  - 8.3.6.4.3. Market size and forecast, by Prescription Type
  - 8.3.6.4.4. Market size and forecast, by Distribution Channel
  - 8.3.6.5. Spain
  - 8.3.6.5.1. Market size and forecast, by Product Type
  - 8.3.6.5.2. Market size and forecast, by Disease Type
  - 8.3.6.5.3. Market size and forecast, by Prescription Type
  - 8.3.6.5.4. Market size and forecast, by Distribution Channel
  - 8.3.6.6. Rest of Europe
  - 8.3.6.6.1. Market size and forecast, by Product Type
  - 8.3.6.6.2. Market size and forecast, by Disease Type
  - 8.3.6.6.3. Market size and forecast, by Prescription Type
  - 8.3.6.6.4. Market size and forecast, by Distribution Channel
8.4. Asia-Pacific
- 8.4.1. Key market trends, growth factors and opportunities
- 8.4.2. Market size and forecast, by Product Type
- 8.4.3. Market size and forecast, by Disease Type
- 8.4.4. Market size and forecast, by Prescription Type
- 8.4.5. Market size and forecast, by Distribution Channel
- 8.4.6. Market size and forecast, by country
  - 8.4.6.1. Japan
  - 8.4.6.1.1. Market size and forecast, by Product Type
  - 8.4.6.1.2. Market size and forecast, by Disease Type
  - 8.4.6.1.3. Market size and forecast, by Prescription Type
  - 8.4.6.1.4. Market size and forecast, by Distribution Channel
  - 8.4.6.2. China
  - 8.4.6.2.1. Market size and forecast, by Product Type
  - 8.4.6.2.2. Market size and forecast, by Disease Type
  - 8.4.6.2.3. Market size and forecast, by Prescription Type
  - 8.4.6.2.4. Market size and forecast, by Distribution Channel
  - 8.4.6.3. India
  - 8.4.6.3.1. Market size and forecast, by Product Type
  - 8.4.6.3.2. Market size and forecast, by Disease Type
  - 8.4.6.3.3. Market size and forecast, by Prescription Type
  - 8.4.6.3.4. Market size and forecast, by Distribution Channel
  - 8.4.6.4. Australia
  - 8.4.6.4.1. Market size and forecast, by Product Type
  - 8.4.6.4.2. Market size and forecast, by Disease Type
  - 8.4.6.4.3. Market size and forecast, by Prescription Type
  - 8.4.6.4.4. Market size and forecast, by Distribution Channel
  - 8.4.6.5. South Korea
  - 8.4.6.5.1. Market size and forecast, by Product Type
  - 8.4.6.5.2. Market size and forecast, by Disease Type
  - 8.4.6.5.3. Market size and forecast, by Prescription Type
  - 8.4.6.5.4. Market size and forecast, by Distribution Channel
  - 8.4.6.6. Rest of Europe
  - 8.4.6.6.1. Market size and forecast, by Product Type
  - 8.4.6.6.2. Market size and forecast, by Disease Type
  - 8.4.6.6.3. Market size and forecast, by Prescription Type
  - 8.4.6.6.4. Market size and forecast, by Distribution Channel
8.5. LAMEA
- 8.5.1. Key market trends, growth factors and opportunities
- 8.5.2. Market size and forecast, by Product Type
- 8.5.3. Market size and forecast, by Disease Type
- 8.5.4. Market size and forecast, by Prescription Type
- 8.5.5. Market size and forecast, by Distribution Channel
- 8.5.6. Market size and forecast, by country
  - 8.5.6.1. Brazil
  - 8.5.6.1.1. Market size and forecast, by Product Type
  - 8.5.6.1.2. Market size and forecast, by Disease Type
  - 8.5.6.1.3. Market size and forecast, by Prescription Type
  - 8.5.6.1.4. Market size and forecast, by Distribution Channel
  - 8.5.6.2. South Africa,
  - 8.5.6.2.1. Market size and forecast, by Product Type
  - 8.5.6.2.2. Market size and forecast, by Disease Type
  - 8.5.6.2.3. Market size and forecast, by Prescription Type
  - 8.5.6.2.4. Market size and forecast, by Distribution Channel
  - 8.5.6.3. Saudi Arabia
  - 8.5.6.3.1. Market size and forecast, by Product Type
  - 8.5.6.3.2. Market size and forecast, by Disease Type
  - 8.5.6.3.3. Market size and forecast, by Prescription Type
  - 8.5.6.3.4. Market size and forecast, by Distribution Channel
  - 8.5.6.4. Rest of LAMEA
  - 8.5.6.4.1. Market size and forecast, by Product Type
  - 8.5.6.4.2. Market size and forecast, by Disease Type
  - 8.5.6.4.3. Market size and forecast, by Prescription Type
  - 8.5.6.4.4. Market size and forecast, by Distribution Channel

CHAPTER 9: COMPETITIVE LANDSCAPE

9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

10.1. Takeda Pharmaceutical Company Ltd.
- 10.1.1. Company overview
- 10.1.2. Key Executives
- 10.1.3. Company snapshot
- 10.1.4. Operating business segments
- 10.1.5. Product portfolio
- 10.1.6. Business performance
10.2. AbbVie Inc.
- 10.2.1. Company overview
- 10.2.2. Key Executives
- 10.2.3. Company snapshot
- 10.2.4. Operating business segments
- 10.2.5. Product portfolio
- 10.2.6. Business performance
- 10.2.7. Key strategic moves and developments
10.3. Abbott Laboratories
- 10.3.1. Company overview
- 10.3.2. Key Executives
- 10.3.3. Company snapshot
- 10.3.4. Operating business segments
- 10.3.5. Product portfolio
- 10.3.6. Business performance
10.4. Sanofi S.A.
- 10.4.1. Company overview
- 10.4.2. Key Executives
- 10.4.3. Company snapshot
- 10.4.4. Operating business segments
- 10.4.5. Product portfolio
- 10.4.6. Business performance
10.5. Bausch Health Companies Inc.
- 10.5.1. Company overview
- 10.5.2. Key Executives
- 10.5.3. Company snapshot
- 10.5.4. Operating business segments
- 10.5.5. Product portfolio
- 10.5.6. Business performance
- 10.5.7. Key strategic moves and developments
10.6. Bayer AG
- 10.6.1. Company overview
- 10.6.2. Key Executives
- 10.6.3. Company snapshot
- 10.6.4. Operating business segments
- 10.6.5. Product portfolio
- 10.6.6. Business performance
10.7. AstraZeneca plc
- 10.7.1. Company overview
- 10.7.2. Key Executives
- 10.7.3. Company snapshot
- 10.7.4. Operating business segments
- 10.7.5. Product portfolio
- 10.7.6. Business performance
10.8. Ironwood Pharmaceuticals, Inc.
- 10.8.1. Company overview
- 10.8.2. Key Executives
- 10.8.3. Company snapshot
- 10.8.4. Operating business segments
- 10.8.5. Product portfolio
- 10.8.6. Business performance
- 10.8.7. Key strategic moves and developments
10.9. Prestige Consumer Healthcare Inc.
- 10.9.1. Company overview
- 10.9.2. Key Executives
- 10.9.3. Company snapshot
- 10.9.4. Operating business segments
- 10.9.5. Product portfolio
- 10.9.6. Business performance
10.10. Ardelyx Inc.
- 10.10.1. Company overview
- 10.10.2. Key Executives
- 10.10.3. Company snapshot
- 10.10.4. Operating business segments
- 10.10.5. Product portfolio
- 10.10.6. Key strategic moves and developments

便秘治療市場：製品タイプ別、疾患タイプ別、処方タイプ別、流通チャネル別：世界の機会分析と産業予測、2023～2032年

Constipation Treatment Market By Product Type, By Disease Type, By Prescription Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章便秘治療市場：製品タイプ別

第5章便秘治療市場：疾患タイプ別

第6章便秘治療市場：処方タイプ別

第7章便秘治療市場：流通チャネル別

第8章便秘治療市場：地域別

第9章競争情勢

第10章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Product Type

By Disease Type

By Prescription Type

By Distribution Channel

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE

CHAPTER 5: CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE

CHAPTER 6: CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE

CHAPTER 7: CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 8: CONSTIPATION TREATMENT MARKET, BY REGION

CHAPTER 9: COMPETITIVE LANDSCAPE

CHAPTER 10: COMPANY PROFILES

便秘治療市場：製品タイプ別、疾患タイプ別、処方タイプ別、流通チャネル別：世界の機会分析と産業予測、2023～2032年

Constipation Treatment Market By Product Type, By Disease Type, By Prescription Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 便秘治療市場：製品タイプ別

第5章 便秘治療市場：疾患タイプ別

第6章 便秘治療市場：処方タイプ別

第7章 便秘治療市場：流通チャネル別

第8章 便秘治療市場：地域別

第9章 競争情勢

第10章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Product Type

By Disease Type

By Prescription Type

By Distribution Channel

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: CONSTIPATION TREATMENT MARKET, BY PRODUCT TYPE

CHAPTER 5: CONSTIPATION TREATMENT MARKET, BY DISEASE TYPE

CHAPTER 6: CONSTIPATION TREATMENT MARKET, BY PRESCRIPTION TYPE

CHAPTER 7: CONSTIPATION TREATMENT MARKET, BY DISTRIBUTION CHANNEL

CHAPTER 8: CONSTIPATION TREATMENT MARKET, BY REGION

CHAPTER 9: COMPETITIVE LANDSCAPE

CHAPTER 10: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章便秘治療市場：製品タイプ別

第5章便秘治療市場：疾患タイプ別

第6章便秘治療市場：処方タイプ別

第7章便秘治療市場：流通チャネル別

第8章便秘治療市場：地域別

第9章競争情勢

第10章企業プロファイル